These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1650391)

  • 21. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should low-molecular-weight heparins replace unfractionated heparin as the agent of choice for adults with deep venous thrombosis?
    Brewer D
    J Fam Pract; 1998 Sep; 47(3):185-92. PubMed ID: 9752370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low molecular weight heparins--state-of-the-art and unsolved issues.
    Breddin HK
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S17-9. PubMed ID: 8180324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From heparins to factor Xa inhibitors and beyond.
    Alban S
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF; Hull RD
    Eur J Med Res; 2004 Apr; 9(4):215-24. PubMed ID: 15210402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low molecular weight heparin therapy: is monitoring needed?
    Boneu B
    Thromb Haemost; 1994 Sep; 72(3):330-4. PubMed ID: 7855780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicentre study on LMW-heparin effectiveness in preventing postsurgical thrombosis.
    Verardi S; Casciani CU; Nicora E; Forzano F; Origone A; Valle I; Catania G; Salanitri G; Salcuni P; Azzarone M
    Int Angiol; 1988; 7(3 Suppl):19-24. PubMed ID: 2850322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic characterization of a medium-molecular-weight heparin in comparison with UFH and LMWH.
    Alban S; Welzel D; Hemker HC
    Semin Thromb Hemost; 2002 Aug; 28(4):369-78. PubMed ID: 12244484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative thrombosis prophylaxis with low molecular weight heparins in elective hip surgery. Clinical and economic considerations.
    Borris LC; Lassen MR; Jensen HP; Andersen BS; Poulsen KA
    Int J Clin Pharmacol Ther; 1994 May; 32(5):262-8. PubMed ID: 7921522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-molecular-weight heparin: from the bench to the orthopedic patient.
    Turpie AG
    Orthopedics; 1997 Feb; 20 Suppl():10-3. PubMed ID: 9048401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical potential of low molecular weight heparins.
    Levine MN; Hirsh J
    Baillieres Clin Haematol; 1990 Jul; 3(3):545-54. PubMed ID: 2176904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thromboembolic prophylaxis with low molecular weight heparin during pregnancy.
    Rasmussen C; Wadt J; Jacobsen B
    Int J Gynaecol Obstet; 1994 Nov; 47(2):121-5. PubMed ID: 7843480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Low molecular weight heparins].
    Drouet L
    Presse Med; 1993 Dec; 22(40):2002-8. PubMed ID: 8127804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of an intervention on the prescription and biological surveillance of low-molecular weight heparins in medicine].
    Fiessinger JN; Chatellier G
    Presse Med; 1996 Nov; 25(36):1777-80. PubMed ID: 8991025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-molecular-weight heparins and heparinoids and their use in acute or progressing ischemic stroke.
    Gordon DL; Linhardt R; Adams HP
    Clin Neuropharmacol; 1990 Dec; 13(6):522-43. PubMed ID: 1703455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The future of low molecular weight heparins in the curative treatment of deep venous thrombosis].
    St-Louis J; St-Louis JM
    Union Med Can; 1994 Mar; 123(3):147-51. PubMed ID: 8184510
    [No Abstract]   [Full Text] [Related]  

  • 38. Low molecular weight heparin(s).
    Barrowcliffe TW
    Br J Haematol; 1995 May; 90(1):1-7. PubMed ID: 7786769
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparative pharmacology of low molecular weight heparins: implications of manufacturing processes on biological effects.
    Doutremepuich C; Guyot M; Lalanne MC; Deharo E; Walenga JM; Fareed J
    Thromb Res; 1989 Aug; 55(4):419-26. PubMed ID: 2554524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Could non steroidal anti-inflammatory drugs be used to potentiate L.M.W.H. activity in thrombosis? (Part II).
    Doutremepuich F; Lalanne MC; Slimani M; Doutremepuich C
    Thromb Res; 1992 May; 66(4):445-9. PubMed ID: 1329259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.